Blue Trust Inc. Has $389,000 Position in Charles River Laboratories International, Inc. $CRL

Blue Trust Inc. boosted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 6.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,562 shares of the medical research company’s stock after acquiring an additional 155 shares during the quarter. Blue Trust Inc.’s holdings in Charles River Laboratories International were worth $389,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of CRL. Brooklyn Investment Group increased its position in shares of Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after purchasing an additional 86 shares in the last quarter. Cromwell Holdings LLC increased its holdings in shares of Charles River Laboratories International by 542.9% during the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock worth $27,000 after buying an additional 152 shares in the last quarter. HM Payson & Co. acquired a new stake in shares of Charles River Laboratories International during the first quarter worth approximately $31,000. Family Legacy Financial Solutions LLC acquired a new stake in shares of Charles River Laboratories International during the second quarter worth approximately $71,000. Finally, ORG Wealth Partners LLC increased its holdings in Charles River Laboratories International by 49.8% during the 2nd quarter. ORG Wealth Partners LLC now owns 496 shares of the medical research company’s stock valued at $77,000 after purchasing an additional 165 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Up 2.3%

Shares of NYSE CRL opened at $170.85 on Tuesday. The firm has a market capitalization of $8.41 billion, a PE ratio of -128.46, a price-to-earnings-growth ratio of 4.47 and a beta of 1.50. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $230.02. The firm’s 50-day moving average is $159.29 and its 200-day moving average is $147.59.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $983.76 million. During the same period last year, the firm earned $2.80 earnings per share. The business’s revenue for the quarter was up .6% on a year-over-year basis. Equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Activity

In other news, EVP Joseph W. Laplume sold 800 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the transaction, the executive vice president directly owned 24,116 shares in the company, valued at $3,800,681.60. This trade represents a 3.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. raised their price target on Charles River Laboratories International from $145.00 to $160.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Jefferies Financial Group upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and raised their target price for the company from $142.00 to $195.00 in a research note on Tuesday, September 9th. Weiss Ratings restated a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 7th. Finally, Citigroup upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and raised their price objective for the company from $150.00 to $200.00 in a research report on Wednesday, July 9th. Eight equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Charles River Laboratories International has a consensus rating of “Hold” and an average price target of $179.93.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).